{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:51Z","timestamp":1793320611703,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.107771","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:31:59Z","timestamp":1783589519000},"page":"107771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"C.K.","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.F.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.D.","family":"Atmakusuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.P.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Korphaisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tanasanvimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.F.","family":"Kalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.C.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.W.","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Muthukkumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2026.107771_bib2","series-title":"Global Cancer Observatory: Cancer Today","year":"2024"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl15257","article-title":"Epidemiology of hepatocellular carcinoma in the Asia-Pacific region","volume":"10","author":"Zhu","year":"2016","journal-title":"Gut Liver"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107771_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107771_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107771_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"issue":"5 Pt 1","key":"10.1016\/j.esmoop.2026.107771_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107771_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107771_bib11","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.3390\/cancers14184473","article-title":"Changes in the epidemiology of hepatocellular carcinoma in Asia","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2026.107771_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1527328","article-title":"Global burden and international disparities in NASH-associated liver cancer: mortality trends (1990-2021) and future projections to 2045","volume":"13","author":"Nie","year":"2025","journal-title":"Front Public Health"},{"issue":"10190","key":"10.1016\/j.esmoop.2026.107771_bib13","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/S0140-6736(18)32744-2","article-title":"Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study","volume":"393","author":"Manthey","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107771_bib16","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107771_bib17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12885-024-12031-0","article-title":"Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.107771_bib19","article-title":"Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis","volume":"2016","author":"Yuan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107771_bib20","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107771_bib21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib22","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2026.107771_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940473","article-title":"Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?","volume":"12","author":"Gonvers","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2026.107771_bib24","article-title":"Clinical applications of liquid biopsy in hepatocellular carcinoma","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107771_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11912-025-01681-3","article-title":"Liquid biopsy in hepatocellular carcinoma: ctDNA as a potential biomarker for diagnosis and prognosis","volume":"27","author":"Yang","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.esmoop.2026.107771_bib26","article-title":"Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/jgh.15227","article-title":"Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA","volume":"36","author":"Hirai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"issue":"17","key":"10.1016\/j.esmoop.2026.107771_bib28","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-18-3477","article-title":"Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma","volume":"25","author":"Cai","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2026.107771_bib29","article-title":"Prognostic value of circulating tumour DNA in Asian patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"2022","author":"Liu","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmoop.2026.107771_bib31","article-title":"Evaluation of the combined application of AFP, AFP-L3%, and DCP for hepatocellular carcinoma diagnosis: a meta-analysis","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3748\/wjg.v19.i3.339","article-title":"Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP","volume":"19","author":"Choi","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/cancers15010301","article-title":"The diagnostic approach towards combined hepatocellular-cholangiocarcinoma-state of the art and future perspectives","volume":"15","author":"Eschrich","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107771_bib34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.21873\/invivo.11413","article-title":"PIVKA-II as a potential new biomarker for hepatocellular carcinoma \u2013 a pilot study","volume":"32","author":"Svobodova","year":"2018","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib35","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1038\/s41598-024-59174-5","article-title":"Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers16010004","article-title":"The role of PIVKA-II as a predictor of early hepatocellular carcinoma recurrence-free survival after liver transplantation in a low alpha-fetoprotein population","volume":"16","author":"Devillers","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6835","article-title":"PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection","volume":"13","author":"Qiu","year":"2024","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jfma.2021.08.003","article-title":"Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis","volume":"121","author":"Su","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hepr.13892","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines)","volume":"53","author":"Hasegawa","year":"2023","journal-title":"Hepatol Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107771_bib44","first-page":"0","article-title":"Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023","volume":"13","author":"Akahoshi","year":"2024","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000546830","article-title":"Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinoma","volume":"15","author":"Komatsu","year":"2025","journal-title":"Liver Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107771_bib46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.hpb.2024.06.009","article-title":"Meta analysis of radiofrequency ablation versus surgical resection in small and large nodule of hepatocellular carcinoma","volume":"26","author":"Gani","year":"2024","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib47","article-title":"Microwave ablation vs. single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized-controlled trial","volume":"7","author":"Sugimoto","year":"2025","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107771_bib48","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/cancers16071422","article-title":"The current and prospective adjuvant therapies for hepatocellular carcinoma","volume":"16","author":"Du","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.107771_bib49","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1002\/lt.22367","article-title":"What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?","volume":"17","author":"Duvoux","year":"2011","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107771_bib50","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib51","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/tri.13391","article-title":"Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule \u2013 a retrospective study","volume":"32","author":"Shimamura","year":"2019","journal-title":"Transplant Int"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib53","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107771_bib54","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"issue":"4 suppl","key":"10.1016\/j.esmoop.2026.107771_bib55","article-title":"Evaluating the safety of immune checkpoint inhibitors prior to liver transplant","volume":"43","author":"Aceituno","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107771_bib57","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY-PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s43556-024-00170-6","article-title":"mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma","volume":"5","author":"Zhang","year":"2024","journal-title":"Mol Biomed"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107771_bib60","article-title":"Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC \u22645.0 cm","volume":"6","author":"Yang","year":"2024","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107771_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib62","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/hepr.12759","article-title":"Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma","volume":"47","author":"Woo","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.esmoop.2026.107771_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.106094","article-title":"Clinical consensus statement: selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia","volume":"102","author":"Liu","year":"2022","journal-title":"Int J Surg"},{"issue":"10474","key":"10.1016\/j.esmoop.2026.107771_bib65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"issue":"10474","key":"10.1016\/j.esmoop.2026.107771_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.107771_bib67","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib69","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107771_bib70","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107771_bib71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib73","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107771_bib74","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/cancers17060972","article-title":"Evaluating sorafenib (SORA-2) as second-line treatment for unresectable hepatocellular carcinoma: a European retrospective multicenter study","volume":"17","author":"M\u00f6hring","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107771_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MEG.0000000000002466","article-title":"Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma","volume":"35","author":"Kim","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10415","key":"10.1016\/j.esmoop.2026.107771_bib76","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107771_bib77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107771_bib78","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.107771_bib79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107771_bib80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","article-title":"Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis","volume":"25","author":"D\u2019Alessio","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107771_bib81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107771_bib84","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:32:56Z","timestamp":1787848376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926017138"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107771","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment, and follow-up of patients with hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107771"}}